Shopping Cart
- Remove All
- Your shopping cart is currently empty
Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2]. |
In vitro | Aselizumab can form dimers through disulfide linkage with the light chains of the chimeric monoclonal HuDreg-55 [1]. At concentrations ranging from 5 to 500 ng/mL and after 25 minutes of incubation, aselizumab inhibits the L-selectin-dependent adhesion of human lymphocytes to high endothelial venules in frozen lymph node sections [3]. |
In vivo | Aselizumab, administered intravenously at a single dose of 10 mg/kg in cynomolgus monkeys, exhibited an elimination half-life of 12.0 days [3]. |
Alias | HuDreg-55 |
Cas No. | 395639-53-9 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.